Investor Presentation Q1-Q3 2020

6 Investor presentation First nine months of 2020 Novo Nordisk® Sales growth of 7% driven by International Operations and GLP-1 Reported geographic sales split for the first nine months of 2020 Added reported therapy area sales and growth DKK billion ■Insulin ■GLP-1 Other diabetes Obesity Biopharm Growth at CER DKK billion ■North America Operations International Operations Growth at CER 7% -3% 29% 6% 4% 56 48 40 40 56 48 12% International Operations 32 11% 27% 8% 10% 8% 24 4% -2% 16 13% 12% 8 -4 0 -6 ΙΟ EMEA China ROW NAO Total' Insulin GLP-1 Obesity Biopharm 2% 4 12% 2 0 2% -22% -2 37% 1 'Other diabetes' is included in Total IO: International Operations; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; ROW: Rest of World; NAO: North America Operations Note: Unless otherwise specified, sales growth rates are at CER

View entire presentation